Print this page
A Multi-Center Pilot Biomarker Study with Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Primary: To determine clinical cardiopulmonary toxicities per the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAEv5.0)
Secondary: To determine subclinical cardiopulmonary events per abnormal lab values and physiological testing.
Protocol Number:
002524
Phase:
N/A
Applicable Disease Sites:
Lung
Principal Investigator:
Salma Jabbour
Scope:
National
Participating Institutions:
- Rutgers University
For further information about clinical trials, please contact us at 732-235-7356.